Resumen
[0001] The invention relates to a method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell. The inventive method consists in using the study of the protein expression of the bioenergetic function of the mitochondrion, such as the .beta.-catalytic subunit of the H+-ATP synthase, in relation to structural proteins and mitochondrial respiration, such as hsp 60 and cytochrome oxidase subunits I and IV respectively, and said mitochondrial bioenergetic index, (ratio of .beta.-ATPasa/hsp60; .beta.-ATPasa/COX I; .beta.-ATPasa/COX IV) which relates to the cellular protein expression of the glycolytic pathway, such as glyceraldehyde-3-phosphate dehydrogenase and pyruvate kinase M, in order to generate the bioenergetic index of the cell.
Reivindicaciones
1. Method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell, characterized because it uses the subunit β of the H(+)-ATP synthase of the mitochondrion as a marker of expression, where the type of cancer is the kidney, colon, stomach, lung and mamma cancer. 2. Method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell, according to claim 1, characterized by the use of immunological techniques, such as western-blot, immunohistochemistry, etcetera... 3. Method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell, according to both previous claims characterized by the use of the mitochondrial bioenergetic index which is expressed by the ratio β-F1-ATPase/ Hsp 60; β-F1-ATPase/ COX I and/or β-F1-ATPase/ COX IV, where the type of cancer is the kidney, colon, stomach, lung and mamma cancer. 4. Method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell, according to all the previous claims characterized by the use of the bioenergetic index of the cell that is expressed by the ratio β-F1-ATPase/ Hsp 60/GAPDH; β-F1-ATPase/ COX I/ GAPDH and/or β-F1-ATPase/ COX IV/ GAPDH where the type of cancer is the kidney, colon, stomach, lung and mamma cancer. 5. Method for cancer detection, progression analysis and malign tumour prognosis based on the study of metabolic markers of the cell, according to claim 3, characterized by the use of the bioenergetic index of the cell that is expressed by the ratio β-F1-ATPase/ Hsp 60/PK; β-F1-ATPase/ COX I/PK; β-F1-ATPase/ COX TV/PK GAPDH where the type of cancer is the kidney, colon, stomach, lung and mamma cancer.
